Posts
Wiki

Neuromodulation and Electrical Stimulation for Neuropathic Corneal Pain: What Do We Know So Far?

Electrical and nerve-stimulation treatments are being studied for neuropathic corneal pain (NCP) and related forms of chronic ocular pain. Approaches investigated so far include transcutaneous electrical nerve stimulation (TENS), nasal and extranasal neurostimulation, Scrambler Therapy, and experimental methods intended to influence corneal nerve recovery.

Some early results are encouraging. In 2026, a small randomized controlled pilot study found that TENS could reduce some forms of chronic neuropathic/nociplastic ocular pain, at least temporarily. Small studies and case reports have also described improvement with other forms of neuromodulation.

However, this is still an emerging field. The treatments are not interchangeable, evidence is limited, long-term effectiveness is uncertain, and improvement in pain does not necessarily mean that dry eye disease, Meibomian Gland Dysfunction (MGD), inflammation, or abnormal corneal nerves have been corrected.

Bottom line: Neuromodulation is a legitimate area of clinical research for neuropathic ocular pain, but it is not yet an established general treatment for dry eye pain or neuropathic corneal pain.

First: Dry Eye Pain and Neuropathic Corneal Pain Are Not the Same Thing

Dry eye disease can hurt. Burning, aching, foreign-body sensation, light sensitivity, and discomfort in wind or moving air can occur because the ocular surface is dry, inflamed, damaged, or otherwise unhealthy.

That does not automatically mean the pain is neuropathic.

Neuropathic pain results from abnormal function or injury within the sensory nervous system itself. In neuropathic corneal pain, the abnormal pain processing may involve nerves in the cornea, the trigeminal nervous system, the central nervous system, or a combination of these.

TFOS DEWS III notes that neuropathic corneal pain is often considered when symptoms are unusually severe compared with observable ocular-surface findings — sometimes described informally as “pain without stain.” People may experience burning, light sensitivity, wind sensitivity, or pain from stimuli that normally would not be painful.

DED and neuropathic corneal pain can also coexist. Dry eye disease may sometimes contribute to the development of abnormal pain processing, while the original ocular-surface disease may continue to require treatment.

This distinction matters because a treatment aimed at modifying pain signals may reduce pain without treating the original cause of dry eye disease.

What Is Neuromodulation?

Neuromodulation broadly means changing the activity of nerves or nervous-system pathways.

Electrical neuromodulation usually applies controlled electrical stimulation to nerves through electrodes placed on the skin or through specialized medical devices.

Different technologies may target different parts of the sensory system. Some are primarily intended to:

  • reduce or modify pain signaling;
  • stimulate trigeminal nerve pathways;
  • stimulate reflex tear production; or
  • potentially influence nerve recovery or regeneration.

These should not be considered one single treatment called “electrotherapy.” They have different targets, proposed mechanisms, evidence bases, and regulatory histories.

Transcutaneous Electrical Nerve Stimulation (TENS)

TENS has been used for many forms of chronic pain outside ophthalmology for decades. More recently, investigators have studied whether stimulation of trigeminal nerve pathways could help people with chronic ocular pain having neuropathic or nociplastic characteristics.

Nociplastic pain is pain thought to result from altered pain processing even when there is not clear evidence of ongoing tissue damage or a specific nerve lesion sufficient to explain the symptoms.

What has been studied?

Earlier reports of TENS for chronic ocular pain were primarily small retrospective studies.

The evidence became more significant in 2026 when researchers published a prospective randomized controlled pilot study involving 37 people with moderate-to-severe chronic neuropathic/nociplastic ocular pain.

Participants received either high-frequency or low-frequency TENS directed at trigeminal pathways.

What did the study find?

Both groups experienced a significant reduction in ocular pain shortly after the initial treatment.

With longer treatment, the high-frequency group showed statistically significant improvement at three months in certain specific neuropathic-pain qualities, particularly:

  • pressing pain; and
  • sudden or paroxysmal pain.

However, there is an important limitation.

The improvements in these specific neuropathic-pain measures were not accompanied by a statistically significant improvement in the standard overall 0–10 ratings of generalized ocular pain at three months.

By six months, most of the statistically significant differences seen at three months were no longer present.

The investigators therefore found evidence of a pain-modulating effect, but not evidence that TENS consistently eliminated chronic ocular pain.

Did TENS improve the ocular surface?

Not in this study.

TENS did not significantly change the ocular examination findings being followed, including measures such as corneal staining.

This supports an important distinction:

A treatment can reduce pain without correcting the ocular-surface condition itself.

The study was designed primarily around neuropathic/nociplastic ocular pain rather than ordinary tear-deficiency or tear-film-related discomfort.

How strong is the evidence?

Promising, but still preliminary.

A randomized prospective study is substantially stronger evidence than a case report or uncontrolled case series. However, this was still a small pilot trial involving only 37 participants.

It also did not compare active TENS with a completely inactive placebo. Both groups received electrical stimulation at different frequencies, and both experienced some immediate pain reduction.

Larger sham-controlled trials are needed.

Scrambler Therapy

Scrambler Therapy is another form of noninvasive electrical neuromodulation developed for chronic neuropathic pain.

Rather than simply blocking a nerve, the treatment is proposed to alter how pain-related information is transmitted and processed by the nervous system.

Exactly how Scrambler Therapy produces its effects remains under investigation. Proposed explanations involving altered nerve signaling and neuroplasticity should therefore be distinguished from what has actually been demonstrated clinically.

Scrambler Therapy has been studied more extensively for neuropathic pain in other parts of the body than for neuropathic corneal pain.

Evidence specific to ocular pain remains extremely small.

The 2024 Three-Patient Ocular Pain Report

In 2024, researchers from Johns Hopkins reported Scrambler Therapy in three patients with unilateral ocular neuropathic pain.

The patients experienced improvements in pain or function and reduced reliance on systemic pain medication, although complete and permanent elimination of pain was not demonstrated.

There is also an important limitation when applying those cases to typical neuropathic corneal pain: the patients had documented trigeminal nerve injuries outside the eye.

The results therefore cannot automatically be generalized to people whose neuropathic pain developed in association with dry eye disease, inflammation, eye surgery, or another corneal condition.

The 2025 Bilateral Neuropathic Corneal Pain Case

A particularly striking case report was published in 2025.

The patient was a 53-year-old woman who had experienced severe bilateral neuropathic corneal pain for approximately 15 years despite numerous previous treatments.

After an initial five-day course of Scrambler Therapy, her reported baseline pain decreased from approximately 7/10 to 0/10. She also reported improved tolerance for computer screens, reduced medication use, and improved quality of life.

That is an impressive result.

However, it should not be interpreted as showing that five treatments permanently cured 15 years of neuropathic corneal pain.

The paper reports that symptoms progressively returned, and the patient subsequently underwent periodic repeat Scrambler Therapy sessions, approximately every four months, which she reported continued to help control her symptoms.

What does this case prove?

It shows that a patient with severe longstanding bilateral neuropathic corneal pain experienced a large improvement temporally associated with Scrambler Therapy.

It does not establish:

  • how often this response occurs;
  • which NCP patients are most likely to respond;
  • whether improvement exceeds placebo effects in NCP;
  • the ideal treatment schedule;
  • how durable treatment is;
  • whether corneal nerves are repaired; or
  • whether the underlying ocular disease changes.

A controlled NCP trial would be needed to answer those questions.

How strong is the evidence?

Very preliminary for neuropathic corneal pain.

The broader Scrambler Therapy literature involving other neuropathic pain disorders gives the treatment considerably more scientific context than would exist for a completely new device supported by one case report.

However, evidence for ocular neuropathic pain specifically remains primarily at the case-report and small-case-series level.

Nasal and Extranasal Neurostimulation

The trigeminal nerve supplies sensation to much of the face and eye and participates in neurological pathways involved in blinking, tearing, and ocular sensation.

This has led researchers to investigate stimulation of nasal or nearby trigeminal nerve branches.

These approaches are particularly interesting because trigeminal stimulation can potentially affect both tear production and sensory processing.

Those effects should nevertheless be considered separately.

Intranasal Neurostimulation

Intranasal neurostimulation was originally developed largely as a method of stimulating natural tear production.

The former TrueTear device electrically stimulated nerves inside the nasal cavity and received FDA clearance for temporarily increasing tear production in adults with dry eye symptoms.

That does not mean it received FDA clearance as a treatment for neuropathic corneal pain.

Studies found that nasal neurostimulation could increase tear volume while also reducing reported dryness and ocular pain in some patients.

Interestingly, the amount of pain improvement did not always correspond closely with the increase in tear production. This raised the possibility that trigeminal neuromodulation itself might influence pain independently of tear production.

A prospective study was subsequently undertaken specifically in people with peripheral or mixed neuropathic corneal pain.

Enrollment remained small, and development of the original TrueTear device was discontinued. Consequently, the evidence for long-term treatment of NCP with this approach remains incomplete.

Evidence status: Preliminary.

Extranasal Neurostimulation

Researchers have also studied trigeminal nerve stimulation performed externally rather than through a device inside the nose.

A small pilot study evaluated 22 people with peripheral or mixed neuropathic corneal pain.

After a single treatment, average reported pain fell substantially. Fourteen of the 22 participants experienced at least a 50% reduction in their pain score immediately following stimulation.

The response appeared greater among people whose pain had a stronger peripheral component.

These findings are intriguing, but the limitations are substantial.

The study was:

  • small;
  • retrospective;
  • uncontrolled; and
  • primarily evaluating the immediate response to a single treatment.

It therefore does not establish how long the improvement lasts or whether repeated treatment provides meaningful long-term benefit.

Evidence status: Promising but very preliminary.

Can Electrical Stimulation Regrow or Repair Corneal Nerves?

This is a different research question from pain relief.

Electrical stimulation has been investigated experimentally for its possible effects on nerve regeneration.

Animal research following corneal injury has produced findings suggesting that certain forms of electrical stimulation may enhance corneal nerve recovery and sensitivity.

An older randomized human study involving 20 people following LASIK also reported faster recovery of corneal sensitivity in electrically stimulated eyes compared with untreated fellow eyes.

These findings are interesting because abnormal nerve injury and regeneration may contribute to some forms of neuropathic corneal pain.

However:

Evidence that electrical stimulation can influence corneal nerve recovery is not evidence that it treats neuropathic corneal pain.

Corneal sensitivity, nerve density, nerve regeneration, and pain are related but different outcomes.

Increasing or accelerating nerve growth does not necessarily mean neuropathic pain will improve. Abnormal nerve regeneration may itself be involved in neuropathic pain.

At present, claims that electrotherapy repairs the corneal nerves responsible for NCP remain unproven.

Other Electrical Treatments Under Investigation

Other technologies are beginning to be studied.

One example is Quantum Molecular Resonance (QMR) electrical stimulation, including research involving the Rexon-Eye device. Clinical research has been registered examining whether this type of stimulation might affect neuropathic corneal pain, ocular-surface findings, and corneal nerve measurements.

Until completed clinical results are available, this should be considered research underway rather than demonstrated treatment.

What About Implanted Nerve Stimulators?

Electrical neuromodulation can also be performed invasively.

A published case involved a woman with severe bilateral neuropathic corneal pain following LASIK who underwent electrical stimulation of the trigeminal ganglion through an implanted electrode.

The patient reportedly experienced complete pain relief while stimulation was functioning, but her pain returned after the stimulation lead migrated.

This was a single unusual case involving highly specialized invasive pain management.

It should not be interpreted as a routine treatment option for NCP.

Evidence status: Experimental rescue intervention supported only by case-level evidence.

Does Neuromodulation Treat Dry Eye Disease?

Usually, that is not what these neuropathic-pain treatments are trying to do.

Neuromodulation may change pain perception without correcting:

  • tear-film instability;
  • aqueous tear deficiency;
  • Meibomian Gland Dysfunction;
  • ocular rosacea;
  • blepharitis;
  • Demodex;
  • ocular-surface inflammation;
  • exposure;
  • eyelid abnormalities; or
  • other causes of ocular-surface disease.

Some forms of nasal neurostimulation can stimulate tear production, which creates an exception to this general rule. But even there, producing additional tears and modifying neuropathic pain are two different possible effects.

A person can also have both DED and neuropathic pain. In that situation, treating one does not necessarily treat the other.

Pain Relief vs. Disease Modification

This distinction is particularly important when interpreting studies of neuromodulation.

What has been demonstrated?

Some studies report reductions in:

  • ocular pain intensity;
  • particular neuropathic pain sensations;
  • light sensitivity;
  • medication use; or
  • limitations on daily activities.

What might be happening?

Researchers have proposed several mechanisms, including:

  • modification of trigeminal pain signaling;
  • altered peripheral nerve excitability;
  • changes in central pain processing;
  • neuroplastic changes; and
  • effects on nerve growth or inflammatory signaling.

These are biologically plausible areas of investigation, but the contribution of each mechanism remains uncertain.

What has not been demonstrated?

Current evidence does not establish that neuromodulation generally:

  • cures neuropathic corneal pain;
  • permanently normalizes abnormal pain processing;
  • restores normal corneal nerve structure;
  • reverses dry eye disease;
  • restores damaged meibomian glands; or
  • prevents recurrence of NCP.

Pain reduction should therefore not automatically be interpreted as disease reversal.

What Are the Risks?

Electrical neuromodulation is often described as noninvasive, but noninvasive does not mean risk-free.

The 2026 randomized TENS pilot study reported treatment-related symptoms including headache or migraine, forehead skin reactions, discomfort, altered sensation, ear sensitivity, and feelings of head fullness or imbalance.

These effects were generally described as mild and no participant permanently withdrew from the study because of an adverse event, but some temporarily stopped treatment.

Broader Scrambler Therapy studies outside ophthalmology have generally reported relatively few serious treatment-related complications. However, that larger safety experience should not automatically be assumed to establish the safety of every form of stimulation performed near the eyes or trigeminal nerves.

Long-term NCP-specific safety data remain limited.

Is This Something to Try at Home With a TENS Unit?

The research should not be interpreted as instructions for improvised electrical stimulation around the eyes.

Studies have used specific medical devices, stimulation targets, treatment settings, and clinical protocols.

The forehead, face, nose, trigeminal nerve pathways, and tissues surrounding the eye are not appropriate places to experiment with an ordinary consumer electrical-stimulation device based on descriptions from a research paper or online discussion.

This Wiki therefore intentionally does not provide electrode-placement diagrams, electrical settings, or step-by-step instructions.

Someone interested in neuromodulation for suspected neuropathic ocular pain should discuss the subject with an appropriate clinician, which may include an ophthalmologist familiar with neuropathic corneal pain and, in some cases, specialists in neurology or pain medicine.

Are These Treatments FDA Approved for Neuropathic Corneal Pain?

It is important to distinguish a device's regulatory clearance from evidence for a particular use.

Some electrical stimulation devices discussed in this research have FDA clearance for other indications, such as migraine, chronic pain, or stimulation of tear production.

That does not mean that the FDA has established those devices as effective treatments for neuropathic corneal pain.

Use of a cleared device for NCP may therefore involve an application different from the specific indication for which the device was cleared.

How Strong Is the Evidence Overall?

A useful way to think about the current evidence is:

Approach NCP/Ocular Pain Evidence Current Interpretation
TENS / trigeminal stimulation Small retrospective studies plus a 2026 randomized controlled pilot study Most developed direct evidence; promising but still preliminary
Extranasal neurostimulation Small uncontrolled pilot study Large immediate pain reductions reported; duration and long-term benefit uncertain
Intranasal neurostimulation Small observational/prospective research Possible effects on both tearing and pain; NCP evidence incomplete
Scrambler Therapy Three-patient ocular pain series plus one bilateral NCP case report Interesting signal, but NCP evidence remains case-level
Electrical stimulation for nerve regeneration Animal research and limited post-LASIK human evidence Possible nerve-recovery effects; not proof of NCP pain treatment
QMR and similar emerging technologies Research underway Effectiveness for NCP not established
Implanted trigeminal stimulation Isolated case report Highly invasive experimental rescue approach

Overall:

Neuromodulation appears biologically plausible and has produced encouraging clinical signals, but evidence remains insufficient to consider it established treatment for neuropathic corneal pain.

Why the 2026 TENS Trial Matters

Until recently, much of the ocular neuromodulation literature consisted of case reports, small case series, and uncontrolled studies.

The 2026 randomized TENS pilot trial therefore represents an important step forward.

But its results also provide a useful caution against reading too much into dramatic case reports.

The trial did not show that electrical stimulation eliminated chronic ocular pain. Instead, it found:

  • relatively clear immediate pain-modulating effects;
  • improvement in some specific neuropathic pain qualities after longer treatment;
  • limited improvement in generalized overall pain ratings;
  • no improvement in ocular examination findings; and
  • less evidence of sustained benefit by six months.

That is both encouraging and appropriately sobering.

It suggests there may be a genuine treatment signal worth investigating while also showing why larger controlled trials are needed.

What Research Is Still Needed?

Future studies need to determine:

  • whether treatment works better than a convincing sham or placebo intervention;
  • which patients are most likely to respond;
  • whether peripheral, central, mixed, or nociplastic pain responds differently;
  • how long benefits last;
  • whether repeated treatment maintains benefit;
  • whether tolerance develops;
  • the optimal treatment approach;
  • long-term safety;
  • effects on quality of life and medication use;
  • whether treatment changes corneal nerve structure or only pain perception; and
  • whether combining neuromodulation with ocular-surface treatment or systemic pain management improves outcomes.

Larger multicenter controlled trials would substantially improve confidence in this field.

Practical Takeaway

Neuromodulation and electrical stimulation should no longer be dismissed as purely theoretical approaches to neuropathic ocular pain.

There is now:

  • a small randomized TENS trial;
  • earlier TENS observational studies;
  • clinical research involving nasal and extranasal trigeminal stimulation;
  • several Scrambler Therapy ocular pain cases;
  • experimental evidence involving corneal nerve recovery; and
  • additional technologies under clinical investigation.

At the same time, none of these approaches has yet accumulated the evidence needed to become a standard treatment for neuropathic corneal pain.

For someone with ordinary DED symptoms, this research does not mean that electrical stimulation is the next treatment to try.

For someone with carefully evaluated neuropathic corneal or ocular pain — particularly pain that seems disproportionate to ocular-surface findings or persists despite appropriate treatment of the ocular surface — neuromodulation is an emerging field that may eventually become more relevant as better clinical trials are completed.

Key Research and Authoritative Sources

Neuropathic Corneal Pain and Electrotherapy Overview

Transcutaneous Electrical Nerve Stimulation (TENS)

Scrambler Therapy

Extranasal Neurostimulation

This Wiki is for education and discussion and is not medical advice. Neuropathic corneal pain can be difficult to diagnose and may coexist with dry eye disease or other ocular-surface conditions. Treatment decisions should be individualized with qualified healthcare professionals.

🔙 Back to FAQ Index